CTA095 induces apoptosis in Src inhibitor resistant prostate cancer cells through Myc and BCL2 inhibition.

<p>PC3-AZD20 (PC3 cell resistant to 20 μM AZD0530) cells were seeded at 10⁶ cells/well in 6 well plates overnight. The cells were treated with AZD0530 or CTA095 at 10 μM. Apoptosis was analyzed using Annexin-V FITC apoptosis detection kit (A). The mRNA levels of Myc and BCL2 were measured using real-time PCR (B). pEtk, Etk, pSrc, Src, pStat3, Stat3, Myc and BCL2 levels were measured using the corresponding antibodies through Western blot (C). Columns, mean; bars, standard deviation, n = 3.